PathomIQ's AI-powered tool shows promise in assessing risk for metastasis in non-metastatic castration-resistant prostate cancer (nmCRPC)

/PRNewswire/ -- New data released today at the American Society of Clinical Oncology (ASCO) Annual Meeting highlighted the application of PathomIQ Inc.'s...

Related Keywords

United States ,American ,George Wilding ,Janssen Biotech Inc ,Pathomiq Inc ,American Society Of Clinical Oncology ,American Society ,Clinical Oncology ,Annual Meeting ,Whole Slide Images ,Chief Medical Officer ,Genitourinary Cancer ,Penile Abstract ,Poster Board ,Janssen Biotech ,